Health Canada is currently assessing nine submissions for generic versions of popular weight loss medications, a move that experts believe could lead to lower prices. These submissions in Canada pertain to generic forms of semaglutide, the active component in Novo Nordisk’s injectable prescription drugs Ozempic and Wegovy, approved by Health Canada for diabetes and weight loss, respectively. These medications belong to the glucagon-like peptide-1 (GLP-1) therapy class, which mimics a natural gut hormone to regulate blood sugar levels, slow digestion, and increase satiety. Side effects of semaglutide may include nausea, vomiting, diarrhea, stomach pain, fatigue, constipation, and headaches.
Canada stands as the sole country where Novo Nordisk’s patent for semaglutide drugs has expired, potentially allowing for the end of “regulatory exclusivity” on Jan. 4. This development positions Canada to potentially offer more affordable versions of Ozempic and Wegovy to individuals with prescriptions, although immediate availability is improbable.
Novo Nordisk recently introduced a pill form of Wegovy in the U.S., with Canada awaiting further information on its availability. Health Canada has not confirmed the submission of a pill version of Wegovy or a generic alternative, emphasizing regular updates on submissions for review. Novo Nordisk also markets a Health Canada-approved pill containing semaglutide to manage Type 2 diabetes under the name Rybelsus.
Generics, deemed equivalent to brand name drugs by Health Canada, undergo a thorough evaluation process to ensure safety, quality, and efficacy. The approval of generic semaglutide drugs presents complexities due to their biological development compared to simpler chemical manufacturing processes for generics. Lower pricing for generics stems from reduced research costs for manufacturers post-patent expiration.
Factors influencing pricing include the drug’s formulation, availability of branded counterparts, and dosing. Although challenges exist, the arrival of cheaper alternatives is anticipated to benefit patients seeking GLP-1 medications for weight loss, with potential monthly costs decreasing significantly. The advent of generics is viewed favorably, particularly for individuals lacking insurance coverage or facing affordability barriers. Notably, major pharmaceutical companies such as Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada are among those applying for generic submissions reviewed by Health Canada.